Stock News•3 weeks ago
AstraZeneca drug prices evolving in response to Trump policy, executive says
AstraZeneca is adjusting new drug launch pricing in response to Trump's most-favoured-nation policy, a senior executive said Monday.
MarketLens
Why Are Institutional Giants Like Manulife Betting Big on AstraZeneca
3 months ago
SHARE THIS ON:
Exclusive Content for Pro Members
Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.
SHARE THIS ON:
Related Articles
Why Are Lawmakers Betting Big on Citigroup
3 months ago
Why is eBay betting big on Depop
6 months ago
Category
You may also like
Stock News•4 weeks ago
Astrazeneca Plc $AZN Shares Acquired by DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale boosted its AstraZeneca holdings by 4,529% in Q1, acquiring 3.7M additional shares. The stake now represents ~1.2% of the fund's portfolio.
Stock News•2 months ago
Can AstraZeneca's Expanding Cancer Portfolio Sustain Momentum?
AstraZeneca’s oncology sales reached $6.8B in Q1 2026, driven by strong performance across its core cancer drug portfolio. The company expects continued momentum as new product launches and late-stage...
Stock News•3 months ago
Which Pharma Giant Offers Better Growth: AstraZeneca or AbbVie?
AstraZeneca and AbbVie present distinct investment profiles based on their respective drug pipelines, valuation metrics, and dividend policies. Investors must weigh these factors against specific loss...
Breaking News
View All →Featured Articles
Top Headlines
Stock News•1 hour ago
Here's Why Nvidia (NVDA) Fell More Than Broader Market
Stock News•1 hour ago
Pence: NVDA "Pivotal Chokepoint" of AI & Likes MSFT, AMZN, GOOGL in Mag 7
Stock News•2 hours ago
QYLD Holders Left $56,700 Per $10,000 on the Table Chasing Twelve Years of Monthly Income
Stock News•2 hours ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alphabet Inc. - GOOG
Stock News•2 hours ago